EGFR and gastric adenocarcinoma: Our study addresses this gap by screening pairwise pharmacological interactions of EGFR, mTOR, and c-MET inhibitors with chemotherapeutics from five distinct groups in gastric adenocarcinoma cells, rigorously inspecting the kinetics of cell death.